Interim Results of a Phase II/III Multicenter Randomized Clinical Trial of AVIFAVIR in Hospitalized Patients with COVID-19

  1. Andrey A. Ivashchenko
  2. Kirill A. Dmitriev
  3. Natalia V. Vostokova
  4. Valeria N. Azarova
  5. Andrew A. Blinow
  6. Alina N. Egorova
  7. Ivan G. Gordeev
  8. Alexey P. Ilin
  9. Ruben N. Karapetian
  10. Dmitry V. Kravchenko
  11. Nikita V. Lomakin
  12. Elena A. Merkulova
  13. Natalia A. Papazova
  14. Elena P. Pavlikova
  15. Nikolay P. Savchuk
  16. Elena N. Simakina
  17. Tagir A. Sitdekov
  18. Elena A. Smolyarchuk
  19. Elena G. Tikhomolova
  20. Elena V. Yakubova
  21. Alexandre V. Ivachtchenko
2 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.

Related articles

Related articles are currently not available for this article.